Osteoporosis International

, Volume 16, Issue 4, pp 372–379 | Cite as

Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women

  • Robert Lindsay
  • J. Christopher Gallagher
  • Michael Kleerekoper
  • James H. Pickar
Original Article

Abstract

Lower doses of conjugated estrogens (CE) alone or combined with lower doses of medroxyprogesterone acetate (MPA) increase mean bone mineral density (BMD) from baseline at the spine and hip in early postmenopausal women. However, not all women on therapy gain BMD. The incidence of continued bone loss (defined as a loss of BMD of >2% from baseline) among women using lower doses of CE and CE/MPA is unknown. This randomized, double-blind, placebo-controlled, multicenter substudy of the Women’s Health, Osteoporosis, Progestin, Estrogen (Women’s HOPE) trial investigated the incidence of continued bone loss with lower-dose CE and CE/MPA. Eight hundred twenty-two healthy postmenopausal women with intact uteri received CE 0.625, CE 0.625/MPA 2.5, CE 0.45, CE 0.45/MPA 2.5, CE 0.45/MPA 1.5, CE 0.3, CE 0.3/MPA 1.5 (all doses in mg/day), or placebo for 2 years along with 600 mg/day of calcium. Changes from baseline in spine and total hip BMD were compared among treatment groups in an intent-to-treat analysis. At 12 months, <10% of women on active treatment lost >2% of spinal BMD (except CE 0.3/MPA 1.5 [15.6%]), compared with 41.2% of women on placebo. At 24 months, the percentages of women on active treatment who lost >2% of spine BMD ranged from 4.5% with CE 0.45/MPA 1.5–15.6% with CE 0.3/MPA 1.5, compared with 55.2% of women taking placebo. More than 85% of women on active treatment did not experience continued BMD loss at the hip at 12 months and 24 months, in contrast to 30.6% of women on placebo at 12 months and 36.5% at 24 months. Women receiving active treatment who lost >2% of spine or hip BMD also had a lesser reduction in biochemical markers of bone turnover. In summary, continued bone loss among early postmenopausal women treated with lower doses of CE or CE/MPA is uncommon.

Keywords

Bone mineral density Conjugated estrogens Lower doses Medroxyprogesterone acetate Postmenopausal hormone therapy Women’s HOPE trial 

References

  1. 1.
    Writing Group for the PEPI Trial (1996) Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276:1389–1396PubMedGoogle Scholar
  2. 2.
    Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287:2668–2776CrossRefPubMedGoogle Scholar
  3. 3.
    Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedGoogle Scholar
  4. 4.
    Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N et al (2002) V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23:529–539CrossRefPubMedGoogle Scholar
  5. 5.
    Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH (2001) Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 75:1065–1079CrossRefPubMedGoogle Scholar
  6. 6.
    McKeever C, McIlwain H, Greenwald M, Gupta N, Jayawardene S, Huels G et al (2000) An estradiol matrix transdermal system for the prevention of postmenopausal bone loss. Clin Ther 22:845–857CrossRefPubMedGoogle Scholar
  7. 7.
    Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR (2001) Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 185:1180–1185CrossRefPubMedGoogle Scholar
  8. 8.
    Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP (1996) Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 88:587–592CrossRefPubMedGoogle Scholar
  9. 9.
    Hosking D, Chilvers CED, Christiansen C, Ravn P, Wasnich R, Ross P et al (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338:485–492CrossRefPubMedGoogle Scholar
  10. 10.
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC et al (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:1246–1254CrossRefPubMedGoogle Scholar
  11. 11.
    Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S et al (1999) Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 10:330–336CrossRefPubMedGoogle Scholar
  12. 12.
    Delmas PD, Hardy P, Garnero P, Dain M-P (2000) Monitoring individual response to hormone replacement therapy with bone markers. Bone 26:553–560CrossRefPubMedGoogle Scholar
  13. 13.
    Greendale GA, Wells B, Marcus R, Barrett-Connor E (2000) How many women lose bone mineral density while taking hormone replacement therapy? Results from the postmenopausal estrogen/progestin interventions trial. Arch Intern Med 160:3065–3071CrossRefPubMedGoogle Scholar
  14. 14.
    Komulainen M, Kroger H, Tuppurainen MT, Heikkinen A-M, Honkanen R, Saarikoski S (2000) Identification of early postmenopausal women with no bone response to HRT: results of a 5-year clinical trial. Osteoporos Int 11:211–218CrossRefPubMedGoogle Scholar
  15. 15.
    Notelovitz M, John VA, Good WR (2002) Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. Menopause 9:343–353CrossRefPubMedGoogle Scholar
  16. 16.
    Cooper C, Stakkestad JA, Radowicki S, Hardy P, Pilate C, Dain MP et al (1999) Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women. Osteoporos Int 9:358–366CrossRefPubMedGoogle Scholar
  17. 17.
    Delmas PD, Pornel B, Felsenberg D, Garnero P, Hardy P, Pilate C et al (1999) A dose-ranging trial of a matrix transdermal 17 β-estradiol for the prevention of bone loss in early postmenopausal women. Bone 24:517–523CrossRefPubMedGoogle Scholar
  18. 18.
    Committee for Proprietary Medicinal Products (2001) Note for guidance on postmenopausal osteoporosis in women. European Agency for the Evaluation of Medicinal Products, LondonGoogle Scholar
  19. 19.
    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586–1592CrossRefPubMedGoogle Scholar
  20. 20.
    Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH (2001) Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 75:1080–1087CrossRefPubMedGoogle Scholar
  21. 21.
    Pickar JH, Yeh I-T, Wheeler JE, Cunnane MF, Speroff L (2001) Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 76:25–31CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2005

Authors and Affiliations

  • Robert Lindsay
    • 1
  • J. Christopher Gallagher
    • 2
  • Michael Kleerekoper
    • 3
  • James H. Pickar
    • 4
  1. 1.Helen Hayes HospitalWest HaverstrawUSA
  2. 2.Creighton University School of MedicineOmahaUSA
  3. 3.Wayne State University School of MedicineDetroitUSA
  4. 4.Wyeth ResearchCollegevilleUSA

Personalised recommendations